A randomised single-blind study to improve health-related quality of life by treating anaemia of chronic kidney disease with Aranesp® (darbepoetin alfa) in older people: STIMULATE

International Urology and Nephrology

Volumn 46, Issue 2, 2014, Pages 469-475

  Roger, Simon D ^a   Jassal, Sarbjit V ^e   Woodward, Michael C ^b   Soroka, Steven ^d   McMahon, Lawrence P ^c  

^a Renal Research   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anaemia; Chronic kidney disease; Erythropoiesis stimulating agents; Quality of life

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO;

AGED; ANEMIA; ARTICLE; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA; GERIATRIC PATIENT; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEIZURE; SHORT FORM 36; SINGLE BLIND PROCEDURE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANEMIA; EARLY TERMINATION OF CLINICAL TRIALS; ERYTHROPOIETIN; HEALTH STATUS; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; PATIENT SELECTION; QUALITY OF LIFE; QUESTIONNAIRES; RENAL INSUFFICIENCY, CHRONIC; SINGLE-BLIND METHOD;

EID: 84896708929     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0512-1     Document Type: Article

References (27)

1. AIHW (2010) Australia's health 2010. Australia's health no. 12. Cat. no. AUS 122. Canberra: AIHW
2. Hemmelgarn BR, Zhang J, Manns BJ et al (2006) Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 69:2155-2161 (Pubitemid 43882101)
3. Roderick PJ, Atkins RJ, Smeeth L et al (2008) Detecting chronic kidney disease in older people; what are the implications? Age Ageing 37:179-186 (Pubitemid 351445189)
4. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC (2004) Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 104:2263-2268 (Pubitemid 39331821)
5. Hsu CY, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504-510 (Pubitemid 34106294)
6. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U (1991) Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron 58:129-134
7. Horina JH, Schwaberger G, Brussee H, Sauseng-Fellegger G, Holzer H, Krejs GJ (1993) Increased red cell 2,3-diphosphoglycerate levels in haemodialysis patients treated with erythropoietin. Nephrol Dial Transplant 8:1219-1222 (Pubitemid 23342655)
8. Penninx BW, Pahor M, Cesari M et al (2004) Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 52:719-724 (Pubitemid 38596489)
9. Lucca U, Tettamanti M, Mosconi P et al (2008) Association of mild anemia with cognitive, functional, mood and quality of life outcomes in the elderly: the "Health and Anemia" study. PLoS One 3:e1920
10. Thein M, Ershler WB, Artz AS et al (2009) Diminished quality of life and physical function in community-dwelling elderly with anemia. Medicine (Baltimore) 88:107-114
11. den Elzen WP, Gussekloo J (2011) Anaemia in older persons. Neth J Med 69:260-267
12. Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML (2010) Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. Am J Kidney Dis 55:519-534
13. Krause MW, Raja R, Agarwal A et al (2009) Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials. Drugs Aging 26:665-675
14. Silver MR, Agarwal A, Krause M, Lei L, Stehman-Breen C (2008) Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease. Am J Geriatr Pharmacother 6:49-60
15. Hertel JE, Locay HR, Scarlata DS, Prathikanti R, Audhya PK (2006) Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease. Mayo Clin Proc 81:1188-1194 (Pubitemid 44316284)
16. Locatelli F, Olivares J, Walker R et al (2001) Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60:741-747 (Pubitemid 32678918)
17. Pfeffer MA, Burdmann EA, Chen CY et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019-2032
18. Walters SJ, Munro JF, Brazier JE (2001) Using the SF-36 with older adults: a cross-sectional community-based survey. Age Ageing 30:337-343 (Pubitemid 32798966)
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470 (Pubitemid 29135798)
20. Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ (2009) The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis. Arch Intern Med 169:1104-1112
21. Levin A, Djurdjev O, Thompson C et al (2005) Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46:799-811 (Pubitemid 41505453)
22. Roger SD, McMahon LP, Clarkson A et al (2004) Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 15:148-156 (Pubitemid 38020706)
23. Finkelstein FO, Story K, Firanek C et al (2009) Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 4:33-38
24. Nicholas JC (2004) A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta. Drugs Aging 21:187-201
25. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Inter 2(Suppl):279-335
26. McMahon LP, MacGinley R (2012) KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology (Carlton) 17:17-19
27. Parfrey PS, Wish T (2010) Quality of life in CKD patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 55:423-425